LENSAR Reports Incentive Grants Pursuant to Nasdaq Listing Rule 5635(c)(4)

ORLANDO, Fla., Oct. 1, 2024 (GLOBE NEWSWIRE) — LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”) today announced approval by a majority of the independent members of LENSAR’s Board of Directors has two newly granted non-executive stock options to purchase a total of 875 common shares of the Company. The options were granted as significant incentives to any employee who takes up employment with the company from October 1, 2024. The options were granted pursuant to Nasdaq Listing Rule 5635(c)(4).

The options have an exercise price of $4.40 per share, which is the closing price of the Company’s common stock on the grant date. The options vest in an amount equal to 25% of the total amount of the award on the first anniversary of the grant date and in thirty-six substantially equal monthly installments thereafter, subject to the new employee’s continued employment with the Company. Each stock option has a term of 10 years. The options are subject to the terms of LENSAR’s 2024 Employment Inducement Incentive Award Plan and a stock option agreement covering the grant.

About LENSAR

LENSAR is a commercial medical device company focused on the design, development and commercialization of advanced systems for the treatment of cataracts and the treatment of astigmatism as an integral aspect of the cataract procedure. LENSAR has developed its next generation ALLY^® Adaptive Cataract Treatment System, the first platform to integrate proprietary imaging and software with an extremely fast dual-pulse femtosecond laser in a compact, highly ergonomic system. ALLY is designed to transform premium cataract surgery by leveraging LENSAR’s advanced technologies and providing the ability to perform the entire procedure in an operating room or in-office surgical suite, resulting in operational efficiencies and lower overhead costs. ALLY includes LENSAR’s proprietary Streamline^® Software technology designed to help surgeons achieve better results.